HB 1394 - Abortion-Inducing Drugs Safety Act

• Requires physicians prescribing abortion-inducing drugs to follow FDA-approved protocols as outlined in final drug labeling, specifically the Mifeprex regimen (mifepristone and misoprostol) for pregnancies up to 49 days gestation.

• Mandates physicians examine patients and document gestational age and intrauterine pregnancy location before administering drugs, and provide patients with a copy of the drug label and contact information for a contracted backup physician at a hospital.

• Requires physicians to schedule a follow-up visit approximately 14 days after drug administration to confirm complete pregnancy termination and assess bleeding, with documentation of efforts to ensure patient compliance.

• Establishes reporting requirements for physicians to report adverse events to the FDA via MedWatch and the Arkansas State Medical Board within three days of occurrence.

• Violations constitute a Class A misdemeanor, but pregnant women cannot be prosecuted; non-compliant physicians face civil malpractice suits, professional disciplinary action, and potential wrongful death liability, with prevailing plaintiffs entitled to attorney's fees.